Fiscal Year 2015 (FY15) Lung Cancer Research Program (LCRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Concept Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-15-LCRP-CA	All investigators at or above the level of postdoctoral fellow (or equivalent)	 Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer. Emphasis on innovation. Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. Clinical trials not allowed. Preliminary data discouraged. Military relevance strongly encouraged. 	 Maximum funding of \$100,000 in direct costs (plus indirect costs) Period of performance not to exceed 1 year 	Pre-Application (Letter of Intent): July 28, 2015 5:00 p.m. Eastern time (ET) Application: August 11, 2015 11:59 p.m. ET
Career Development Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-15-LCRP-CDA	 Principal Investigator (PI) Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment Must have not received a Career Development Award previously from any programs within the Congressionally Directed Medical Research Programs 	 Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher. Clinical trials not allowed. Preliminary data not required. Military relevance strongly encouraged. 	 Maximum funding of \$240,000 in direct costs (plus indirect costs) Period of performance not to exceed 2 years 	Pre-Application (Preproposal): June 2, 2015 5:00 p.m. ET Preproposal is required; application submission is by invitation only. Invited Application: September 16, 2015 11:59 p.m. ET

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Clinical Exploration Award	 Must have not received more than \$300,000 in total direct costs for previous or concurrent lung cancer research as a PI of one or more federally or privately funded, non-mentored, peer-reviewed grants. Mentor At or above the level of Associate Professor (or equivalent). Must have a proven publication and funding record in lung cancer research. Independent investigators at or above the level of 	Clinical Trials: Supports rapid execution of hypothesis.	Clinical Trials	Pre-Application (Propressed):
 Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-15-LCRP-CEA 	at or above the level of Assistant Professor (or equivalent)	rapid execution of hypothesis-driven, early-phase clinical trials to examine interventions that could have a major impact on lung cancer clinical management. It is anticipated that proposed studies will explore innovative and untested concepts to provide scientific rationale or initial proof-of-principle for larger clinical trials in lung cancer. • Correlative Studies: Supports innovative, hypothesis-based correlative studies that derive from ongoing or completed clinical trials that have the potential to significantly inform treatment strategies, identify subset of	 Maximum funding of \$450,000 in direct costs (plus indirect costs) Period of performance not to exceed 3 years Correlative Studies Maximum funding of \$250,000 in direct costs (plus indirect costs) Period of performance not to exceed 2 years 	(Preproposal): June 2, 2015 5:00 p.m. ET Preproposal is required; application submission is by invitation only. Invited Application: September 16, 2015 11:59 p.m. ET

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		patients for treatment with specific therapies, provide increased understanding of biological changes resulting from the intervention in lung cancer, or provide other insights that will significantly enhance clinical management of lung cancer.		
		The application must include documentation of an existing Investigational New Drug (IND) or Investigational Device Exemption (IDE), if applicable.		
		The proposed study is expected to begin no later than 12 months after the award date.		
		Military relevance strongly encouraged.		

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Idea Development Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-15-LCRP-IDA	Established Investigators: Independent investigators at or above the level of an Assistant Professor (or equivalent) New Investigators: Investigators that meet the following criteria at the application submission deadline date: • Have not previously received a LCRP Idea Development Award or LCRP Early Investigator Synergistic Idea Award • Be within 10 years of first faculty appointment (or equivalent)	 Supports new ideas that are in the early stages of development representing innovative, high-risk/high-gain research. Emphasis is on innovation and impact. New Investigators: Supports applicants early in their faculty appointments or in the process of developing independent research careers. Clinical trials not allowed. Preliminary data required, but may be from outside of lung cancer. Military relevance strongly encouraged. 	 Maximum funding of \$350,000 in direct costs (plus indirect costs) Period of performance not to exceed 2 years 	Pre-Application (Preproposal): June 2, 2015 5:00 p.m. Eastern time Preproposal is required; application submission is by invitation only. Invited Application: September 16, 2015 11:59 p.m. Eastern time